Endometrial large cell neuroendocrine carcinoma: a case report

Endometrial neuroendocrine carcinoma (NEC) is a rare non-endometrioid subtype of endometrial carcinoma characterized by aggressive behavior and poor prognosis. For endometrial large cell neuroendocrine carcinoma (LCNEC), the reported median overall survival (OS) is approximately 11 months, and the 5-year OS rate is approximately 23%; most patients are diagnosed at advanced stages (FIGO stage III/IV). Molecular studies of endometrial NEC remain limited, although alterations involving PTEN and PIK3CA and mismatch repair deficiency (dMMR) have been reported. Herein, we report endometrial LCNEC in a 52-year-old patient harboring the pathogenic POLE exonuclease-domain variant p.V411L, a rarely reported molecular finding in this histological subtype. The patient underwent surgery followed by two cycles of nab-paclitaxel plus carboplatin, external-beam radiotherapy and brachytherapy, and two additional chemotherapy cycles. At the last follow-up on September 9, 2026, no local recurrence or distant metastasis was identified. Molecular testing supported classification as POLE -mutated endometrial carcinoma. This report describes the clinicopathological and molecular characteristics, treatment, and short-term outcome of this rare case.

Authors

Institutions

Publication Details

Journal
Frontiers in Reproductive Health
Published
2026-11-18
DOI
https://doi.org/10.3389/frph.2026.1982595
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Endometrial large cell neuroendocrine carcinoma: a case report

Xuehan Bi, Xi Chen, Xiao Lv, Li Pu
1 links
Frontiers in Reproductive Health
Endometrial and Cervical Cancer Treatments
article

Endometrial large cell neuroendocrine carcinoma: a case report

Xuehan Bi, Xi Chen, Xiao Lv, Li Pu
article en

Abstract

Endometrial neuroendocrine carcinoma (NEC) is a rare non-endometrioid subtype of endometrial carcinoma characterized by aggressive behavior and poor prognosis. For endometrial large cell neuroendocrine carcinoma (LCNEC), the reported median overall survival (OS) is approximately 11 months, and the 5-year OS rate is approximately 23%; most patients are diagnosed at advanced stages (FIGO stage III/IV). Molecular studies of endometrial NEC remain limited, although alterations involving PTEN and PIK3CA and mismatch repair deficiency (dMMR) have been reported. Herein, we report endometrial LCNEC in a 52-year-old patient harboring the pathogenic POLE exonuclease-domain variant p.V411L, a rarely reported molecular finding in this histological subtype. The patient underwent surgery followed by two cycles of nab-paclitaxel plus carboplatin, external-beam radiotherapy and brachytherapy, and two additional chemotherapy cycles. At the last follow-up on September 9, 2026, no local recurrence or distant metastasis was identified. Molecular testing supported classification as POLE -mutated endometrial carcinoma. This report describes the clinicopathological and molecular characteristics, treatment, and short-term outcome of this rare case.

Frontiers in Reproductive HealthVol. 8
First Hospital of Lanzhou University (CN)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon